
    
      The study is designed to explore the safety, tolerability, pharmacokinetics and
      pharmacodynamics of BIND-014 and define a recommended Phase 2 dose of BIND-014.

      All cycles of therapy will consist of the patient taking BIND-014 intravenously once every
      three weeks or weekly for three out of four weeks.
    
  